Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.

Product News
These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information.

EMEND® (fosaprepitant dimeglumine) for Injection
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
29 Jan 2008  FDA Approves EMEND® (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy
 

Gardasil® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
08 Jul 2008  Merck Responds to Questions about Adverse Events Reported following Vaccination with GARDASIL®
 
25 Jun 2008  Merck & Co., Inc Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL® in Women Ages 27 through 45
 
19 Mar 2008  Supplemental Application for GARDASIL®, Merck's Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
 

ISENTRESS™ (raltegravir)
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
06 Feb 2008  Merck's ISENTRESS® (raltegravir) Tablets in Combination with other Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and Increased CD4 Cell Counts Through 48 Weeks of Therapy in Treatment-Experienced Adults
 

Janumet™ (sitagliptin/metformin HCl) tablets
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
24 Apr 2008  Two Merck Medicines Recommended for Approval in the European Union
 

Januvia™ (sitagliptin)
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
09 Jun 2008  A New Analysis Released at ADA: Lower Risk of Symptomatic Hypoglycemia with JANUVIA™ (sitagliptin) Compared to Glipizide on a Background of Metformin in Patients with Type 2 Diabetes
 
07 Jun 2008  New Data Released at Major Diabetes Meeting on Initial Combination Therapy with JANUVIA™ (sitagliptin), Merck's Diabetes Medicine, and Metformin through Two Years of Treatment
 

MEVACOR® (lovastatin)
25 Jan 2008  Merck Receives Not Approvable Letter from FDA for OTC MEVACOR® (lovastatin) 20 mg
 

RotaTeq® (rotavirus vaccine, live, oral, pentavalent)
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
25 Jun 2008  CDC Observes Reduction in Rotavirus Disease After the Introduction of ROTATEQ®, Merck's Rotavirus Vaccine
 

SINGULAIR® (montelukast)
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
27 Mar 2008  Merck Statement on the FDA Early Communication of an Ongoing Safety Review of Montelukast (SINGULAIR™)
 

VYTORIN™ (ezetimibe/simvastatin)
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
30 Mar 2008  Merck/Schering-Plough Pharmaceuticals Comments on Results of the ENHANCE Study
 
28 Mar 2008  Statement on IMPROVE-IT Study
 
25 Jan 2008  Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
 

Zostavax® [Zoster Vaccine Live(Oka/Merck)]
Acrobat PDF file Full Prescribing Information Acrobat PDF file Patient Product Information
15 May 2008  CDC Recommends ZOSTAVAX®, Merck's Shingles Vaccine, for All Appropriate Adults Aged 60 and Older
 

top
 

SITE MAP PRIVACY POLICYTERMS OF USECOPYRIGHT © 1995-2007 MERCK & CO., INC.